Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy
Epilepsia Open2019Vol. 4(3), pp. 420–430
Citations Over TimeTop 10% of 2019 papers
Katri Silvennoinen, Nikola de Lange, Sara Zagaglia, Simona Balestrini, Ganna Androsova, Merel Wassenaar, Pauls Auce, Andreja Avberšek, Felicitas Becker, Bianca Berghuis, Ellen Campbell, Antonietta Coppola, Ben Francis, Stefan Wolking, Gianpiero L. Cavalleri, John Craig, Norman Delanty, Michael R. Johnson, Bobby P.C. Koeleman, Wolfram S. Kunz, Holger Lerche, Anthony G Marson, Terence J. O’Brien, Josemir W. Sander, Graeme J. Sills, Pasquale Striano, Federico Zara, Job van der Palen, Roland Krause, Chantal Depondt, Sanjay M. Sisodiya
Abstract
In people with JME, valproate is an effective AED; levetiracetam emerged as an alternative. Valproate is now contraindicated in women of childbearing potential without special precautions. With appropriate selection and safeguards in place, valproate should remain available as a therapy, including as an alternative for women of childbearing potential whose seizures are resistant to other treatments.
Related Papers
- → Genetic Landscape of Common Epilepsies: Advancing towards Precision in Treatment(2020)95 cited
- → Genetic influences on myoclonic and absence seizures(2003)52 cited
- → When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy(2010)22 cited
- → Juvenile myoclonic epilepsy: Under-diagnosed syndrome(2011)1 cited
- [Juvenile myoclonic epilepsy].(1995)